Health Care Supplies

Xtant Med

Xtant Med released FY2026 Q1 earnings on May 13 Pre-Market EST, actual revenue USD 20.88 M (forecast USD 19.79 M), actual EPS USD -0.022 (forecast USD -0.015)

Xtant Medical Holdings Inc. Q1 Loss of $3.1M, FY Outlook $101M-$105M

Xtant Med to Release FY2026 Q1 Earnings on May 13 Pre-Market EST, Forecast Revenue USD 19.79 M, EPS USD -0.015

Xtant Med released FY2025 Annual Earnings on March 31 Pre-Market (EST), Actual Revenue USD 133.93 M (Forecast USD 132.3 M), Actual EPS USD 0.03 (Forecast USD 0.025)

Xtant Med released FY2025 Q4 earnings on March 31 Pre-Market (EST), actual revenue USD 32.36 M (forecast USD 30.75 M), actual EPS USD 0 (forecast USD -0.005)

Xtant Medical Holdings Reports 2025 Revenue Exceeding Expectations

Xtant Med to Release FY2025 Q4 Earnings on March 31 Pre-Market EST, Forecast Revenue USD 30.75 M, EPS USD -0.005

Xtant Med released FY2025 Q3 earnings on November 10 Pre-Market (EST), actual revenue USD 33.26 M (forecast USD 32.7 M), actual EPS USD 0.0093 (forecast USD -0.005)

Xtant Med released FY2025 9 Months Earnings on November 10 Pre-Market EST, actual revenue USD 68.32 M, actual EPS USD 0.0204

Xtant Med to Release FY2025 Q3 Earnings on November 11, Pre-Market EST; Forecast Revenue USD 32.7M, EPS USD -0.005

Xtant Med released FY2025 Q2 earnings on August 12 Pre-Market EST, actual revenue USD 35.41 M (forecast USD 31.35 M), actual EPS USD 0.02 (forecast USD -0.01)

Xtant Med released FY2025 Semi-Annual earnings on August 12 Pre-Market (EST), actual revenue USD 68.32 M, actual EPS USD 0.0199

Xtant Med to release FY2025 Q2 earnings on August 12 Pre-Market EST, forecast revenue USD 31.35 M, EPS USD -0.01

Xtant Med released FY2025 Q1 earnings on May 12 After-Market EST, actual revenue USD 32.9 M (forecast USD 31.22 M), actual EPS USD 0.0004 (forecast USD -0.01)

Xtant Medical Reports Q1 2025 Earnings and Raises Full-Year Revenue Guidance

Xtant Med to release FY2025 Q1 earnings on May 12 After-Market EST, forecast revenue USD 31.22 M, EPS USD -0.01

Xtant Medical Holdings Launches Trivium™

Xtant Med released FY2024 Annual Earnings on March 6 After-Market (EST), actual revenue $117.27M (forecast $117.5M), actual EPS -$0.123 (forecast -$0.115)

Xtant Med released FY2024 Q4 earnings on March 6 After-Market (EST), actual revenue $31.51M (forecast $31.8M), actual EPS -$0.02 (forecast -$0.015)

Xtant Med to Release FY2024 Q4 Earnings on March 6 After-Market EST, Forecast Revenue 31.8 M USD, EPS -0.015 USD

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Silexion Therapeutics

Micware

GCL Global

MetaVia

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Bristol-Myers Squibb Company

XTNT

Xtant Medical Holdings reported Q1 2026 revenue of $20.9 million, down from $32.9 million year-over-year, with a net loss of $3.1 million. The company reduced its debt by $13.3 million and raised its 2026 revenue guidance to $101–$105 million due to a new product distribution deal. Xtant also secured exclusive U.S. rights to a hemostatic product and hired a sales team to expand its market reach. The annual stockholder meeting is set for August 7, 2026, with new deadlines for proposals and nominations. Analyst rating for XTNT stock is a Buy with a $1.50 price target.

Tip Ranks

Xtant Medical Updates Q1 Results and Raises 2026 Guidance

Earnings Watch

Xtant Med | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 20.88 M

Xtant Medical Reports First Quarter 2026 Financial Results | XTNT Stock News

StockTitan

Xtant Medical Reports First Quarter 2026 Financial Results | XTNT Stock News

Xtant Medical Holdings, Inc. (NYSE American: XTNT) will announce its financial results for Q1 2026 on May 13, 2026, before trading begins. A conference call will be held at 8:30 AM ET, hosted by CEO Sean Browne and CFO Scott Neils. The call can be accessed via dial-in or webcast, with a replay available on the company's website. Xtant Medical focuses on surgical solutions for orthopedic conditions and aims to honor the gift of donation to enhance patients' lives.

Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026 | XTNT Stock News

Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped | XTNT Stock News

Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped | XTNT Stock News

INBX

KYTX

In Wednesday's pre-market session, Axe Compute (NASDAQ:AGPU) saw a significant rise of 148.8% to $12.14, while Kyverna Therapeutics (NASDAQ:KYTX) increased by 15.46% to $11.21. Other gainers included Alpha Compute (NASDAQ:ALP) up 12.71%, Inhibrx Biosciences (NASDAQ:INBX) up 11.54%, and Teleflex (NYSE:TFX) up 10.62%. Conversely, Psyence Biomedical (NASDAQ:PBM) shares fell 13.4% to $8.22, followed by Community Health System (NYSE:CYH) down 11.62%. Clearmind Medicine (NASDAQ:CMND) and Edesa Biotech (NASDAQ:EDSA) also experienced declines.

benzinga_article

Inhibrx Biosciences

Teleflex

Kyverna Therapeutics

Alpha Compute

Axe Compute

Community Health

SPDR S&P Biotech

iShares Biotechnology ETF

iShares US Pharma

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

iShares US Healthcare Providers

VanEck Biotech ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

VG Health

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Health

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Spruce Biosciences

Psyence Biomedical

Clearmind Medicine

Edesa Biotech

Basel Medical

Autonomix Medical

SPRUCE BIOSCIENCES INC

PSYENCE BIOMEDICAL LTD C/WTS 25/01/2029(TO PUR COM)

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Xtant Medical has secured exclusive U.S. distribution rights for HEMOBLAST Bellows, paying a $5.0 million fee to Dilon. The agreement allows Xtant to import, market, and sell the product in the U.S., with Dilon continuing manufacturing in France. Xtant has hired approximately 20 former Dilon sales personnel to aid in commercialization. The company plans to update its full-year 2026 financial guidance in conjunction with Q1 2026 results due to this new arrangement.

TradingView

Xtant Medical Gains Exclusive U.S. Rights to HEMOBLAST Bellows, Pays $5.0M Fee

Xtant Med(XTNT.US)

Xtant Medical Updates Q1 Results and Raises 2026 Guidance

Xtant Med | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 20.88 M

Xtant Medical Reports First Quarter 2026 Financial Results | XTNT Stock News

Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026 | XTNT Stock News

Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped | XTNT Stock News

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Xtant Medical Gains Exclusive U.S. Rights to HEMOBLAST Bellows, Pays $5.0M Fee